Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Arch Biopartners Inc > Older article i found interesting
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by 2019champson Aug 15, 2021 10:19am
131 Views
Post# 33707212

Older article i found interesting

Older article i found interestinghttps://www.frontiersin.org/articles/10.3389/fimmu.2020.01446/full "Complete blood picture of COVID-19 patients usually shows lymphopenia with or without total leukopenia. A lymphocyte count <1.0 109/l has been associated with severe disease (18). a recent research has reported that severe cases of covid-19 tend to have higher neutrophil to lymphocyte ratio (nlr). nlr is calculated from a routine blood picture by dividing the absolute neutrophil count by the absolute lymphocyte count and indicates a patient's overall inflammatory status". ="" 109/l="" has="" been="" associated="" with="" severe="" disease="" (18).="" a="" recent="" research="" has="" reported="" that="" severe="" cases="" of="" covid-19="" tend="" to="" have="" higher="" neutrophil="" to="" lymphocyte="" ratio="" (nlr).="" nlr="" is="" calculated="" from="" a="" routine="" blood="" picture="" by="" dividing="" the="" absolute="" neutrophil="" count="" by="" the="" absolute="" lymphocyte="" count="" and="" indicates="" a="" patient's="" overall="" inflammatory="" status".="">
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities